Grafton DBM + autogenous bone marrow reamings

Grafton DBM is a demineralized bone matrix (DBM) product derived from human allograft tissue, originally developed by Osteotech and currently marketed by Medtronic. It is processed to remove mineral content while preserving the organic matrix, which includes Type I collagen and endogenous growth factors such as bone morphogenetic proteins (BMPs). This composition provides both an osteoconductive scaffold for cell attachment and an osteoinductive signal to promote the differentiation of mesenchymal stem cells into bone-forming osteoblasts. In the specific clinical context of the Emory University Phase 4 trial, Grafton DBM is combined with autogenous bone marrow reamings—harvested during intramedullary nailing (IMN)—to create a composite graft intended to accelerate the healing of closed diaphyseal tibia fractures and reduce the incidence of nonunion or delayed union. The product is available in various formulations, including gel and putty, and is regulated by the FDA as a human tissue product or medical device.

Brand names

Grafton

Other names

Demineralized Bone MatrixDBM